Combined Inhibition of p97 and the Proteasome Causes Lethal Disruption of the Secretory Apparatus in Multiple Myeloma Cells

Holger W. Auner, Anne Marie Moody, Theresa H. Ward, Marianne Kraus, Enrico Milan, Philippa May, Aristeidis Chaidos, Christoph Driessen, Simone Cenci, Francesco Dazzi, Amin Rahemtulla, Jane F. Apperley, Anastasios Karadimitris, Niall Dillon

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Inhibition of the proteasome is a widely used strategy for treating multiple myeloma that takes advantage of the heavy secretory load that multiple myeloma cells (MMCs) have to deal with. Resistance of MMCs to proteasome inhibition has been linked to incomplete disruption of proteasomal endoplasmic-reticulum (ER)-associated degradation (ERAD) and activation of non-proteasomal protein degradation pathways. The ATPase p97 (VCP/Cdc48) has key roles in mediating both ERAD and non-proteasomal protein degradation and can be targeted pharmacologically by small molecule inhibition. In this study, we compared the effects of p97 inhibition with Eeyarestatin 1 and DBeQ on the secretory apparatus of MMCs with the effects induced by the proteasome inhibitor bortezomib, and the effects caused by combined inhibition of p97 and the proteasome. We found that p97 inhibition elicits cellular responses that are different from those induced by proteasome inhibition, and that the responses differ considerably between MMC lines. Moreover, we found that dual inhibition of both p97 and the proteasome terminally disrupts ER configuration and intracellular protein metabolism in MMCs. Dual inhibition of p97 and the proteasome induced high levels of apoptosis in all of the MMC lines that we analysed, including bortezomib-adapted AMO-1 cells, and was also effective in killing primary MMCs. Only minor toxicity was observed in untransformed and non-secretory cells. Our observations highlight non-redundant roles of p97 and the proteasome in maintaining secretory homeostasis in MMCs and provide a preclinical conceptual framework for dual targeting of p97 and the proteasome as a potential new therapeutic strategy in multiple myeloma.

Original languageEnglish
Article numbere74415
JournalPLoS One
Volume8
Issue number9
DOIs
Publication statusPublished - Sep 16 2013

Fingerprint

myeloma
proteasome endopeptidase complex
Proteasome Endopeptidase Complex
Multiple Myeloma
cells
Degradation
protein degradation
endoplasmic reticulum
Cells
Proteolysis
Enzyme inhibition
Proteins
Proteasome Inhibitors
Endoplasmic Reticulum-Associated Degradation
cell lines
Cell Line
Metabolism
degradation
Toxicity
protein metabolism

ASJC Scopus subject areas

  • Agricultural and Biological Sciences(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Combined Inhibition of p97 and the Proteasome Causes Lethal Disruption of the Secretory Apparatus in Multiple Myeloma Cells. / Auner, Holger W.; Moody, Anne Marie; Ward, Theresa H.; Kraus, Marianne; Milan, Enrico; May, Philippa; Chaidos, Aristeidis; Driessen, Christoph; Cenci, Simone; Dazzi, Francesco; Rahemtulla, Amin; Apperley, Jane F.; Karadimitris, Anastasios; Dillon, Niall.

In: PLoS One, Vol. 8, No. 9, e74415, 16.09.2013.

Research output: Contribution to journalArticle

Auner, HW, Moody, AM, Ward, TH, Kraus, M, Milan, E, May, P, Chaidos, A, Driessen, C, Cenci, S, Dazzi, F, Rahemtulla, A, Apperley, JF, Karadimitris, A & Dillon, N 2013, 'Combined Inhibition of p97 and the Proteasome Causes Lethal Disruption of the Secretory Apparatus in Multiple Myeloma Cells', PLoS One, vol. 8, no. 9, e74415. https://doi.org/10.1371/journal.pone.0074415
Auner, Holger W. ; Moody, Anne Marie ; Ward, Theresa H. ; Kraus, Marianne ; Milan, Enrico ; May, Philippa ; Chaidos, Aristeidis ; Driessen, Christoph ; Cenci, Simone ; Dazzi, Francesco ; Rahemtulla, Amin ; Apperley, Jane F. ; Karadimitris, Anastasios ; Dillon, Niall. / Combined Inhibition of p97 and the Proteasome Causes Lethal Disruption of the Secretory Apparatus in Multiple Myeloma Cells. In: PLoS One. 2013 ; Vol. 8, No. 9.
@article{4b2339df438a45b1b1a326018ebaaa0d,
title = "Combined Inhibition of p97 and the Proteasome Causes Lethal Disruption of the Secretory Apparatus in Multiple Myeloma Cells",
abstract = "Inhibition of the proteasome is a widely used strategy for treating multiple myeloma that takes advantage of the heavy secretory load that multiple myeloma cells (MMCs) have to deal with. Resistance of MMCs to proteasome inhibition has been linked to incomplete disruption of proteasomal endoplasmic-reticulum (ER)-associated degradation (ERAD) and activation of non-proteasomal protein degradation pathways. The ATPase p97 (VCP/Cdc48) has key roles in mediating both ERAD and non-proteasomal protein degradation and can be targeted pharmacologically by small molecule inhibition. In this study, we compared the effects of p97 inhibition with Eeyarestatin 1 and DBeQ on the secretory apparatus of MMCs with the effects induced by the proteasome inhibitor bortezomib, and the effects caused by combined inhibition of p97 and the proteasome. We found that p97 inhibition elicits cellular responses that are different from those induced by proteasome inhibition, and that the responses differ considerably between MMC lines. Moreover, we found that dual inhibition of both p97 and the proteasome terminally disrupts ER configuration and intracellular protein metabolism in MMCs. Dual inhibition of p97 and the proteasome induced high levels of apoptosis in all of the MMC lines that we analysed, including bortezomib-adapted AMO-1 cells, and was also effective in killing primary MMCs. Only minor toxicity was observed in untransformed and non-secretory cells. Our observations highlight non-redundant roles of p97 and the proteasome in maintaining secretory homeostasis in MMCs and provide a preclinical conceptual framework for dual targeting of p97 and the proteasome as a potential new therapeutic strategy in multiple myeloma.",
author = "Auner, {Holger W.} and Moody, {Anne Marie} and Ward, {Theresa H.} and Marianne Kraus and Enrico Milan and Philippa May and Aristeidis Chaidos and Christoph Driessen and Simone Cenci and Francesco Dazzi and Amin Rahemtulla and Apperley, {Jane F.} and Anastasios Karadimitris and Niall Dillon",
year = "2013",
month = "9",
day = "16",
doi = "10.1371/journal.pone.0074415",
language = "English",
volume = "8",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "9",

}

TY - JOUR

T1 - Combined Inhibition of p97 and the Proteasome Causes Lethal Disruption of the Secretory Apparatus in Multiple Myeloma Cells

AU - Auner, Holger W.

AU - Moody, Anne Marie

AU - Ward, Theresa H.

AU - Kraus, Marianne

AU - Milan, Enrico

AU - May, Philippa

AU - Chaidos, Aristeidis

AU - Driessen, Christoph

AU - Cenci, Simone

AU - Dazzi, Francesco

AU - Rahemtulla, Amin

AU - Apperley, Jane F.

AU - Karadimitris, Anastasios

AU - Dillon, Niall

PY - 2013/9/16

Y1 - 2013/9/16

N2 - Inhibition of the proteasome is a widely used strategy for treating multiple myeloma that takes advantage of the heavy secretory load that multiple myeloma cells (MMCs) have to deal with. Resistance of MMCs to proteasome inhibition has been linked to incomplete disruption of proteasomal endoplasmic-reticulum (ER)-associated degradation (ERAD) and activation of non-proteasomal protein degradation pathways. The ATPase p97 (VCP/Cdc48) has key roles in mediating both ERAD and non-proteasomal protein degradation and can be targeted pharmacologically by small molecule inhibition. In this study, we compared the effects of p97 inhibition with Eeyarestatin 1 and DBeQ on the secretory apparatus of MMCs with the effects induced by the proteasome inhibitor bortezomib, and the effects caused by combined inhibition of p97 and the proteasome. We found that p97 inhibition elicits cellular responses that are different from those induced by proteasome inhibition, and that the responses differ considerably between MMC lines. Moreover, we found that dual inhibition of both p97 and the proteasome terminally disrupts ER configuration and intracellular protein metabolism in MMCs. Dual inhibition of p97 and the proteasome induced high levels of apoptosis in all of the MMC lines that we analysed, including bortezomib-adapted AMO-1 cells, and was also effective in killing primary MMCs. Only minor toxicity was observed in untransformed and non-secretory cells. Our observations highlight non-redundant roles of p97 and the proteasome in maintaining secretory homeostasis in MMCs and provide a preclinical conceptual framework for dual targeting of p97 and the proteasome as a potential new therapeutic strategy in multiple myeloma.

AB - Inhibition of the proteasome is a widely used strategy for treating multiple myeloma that takes advantage of the heavy secretory load that multiple myeloma cells (MMCs) have to deal with. Resistance of MMCs to proteasome inhibition has been linked to incomplete disruption of proteasomal endoplasmic-reticulum (ER)-associated degradation (ERAD) and activation of non-proteasomal protein degradation pathways. The ATPase p97 (VCP/Cdc48) has key roles in mediating both ERAD and non-proteasomal protein degradation and can be targeted pharmacologically by small molecule inhibition. In this study, we compared the effects of p97 inhibition with Eeyarestatin 1 and DBeQ on the secretory apparatus of MMCs with the effects induced by the proteasome inhibitor bortezomib, and the effects caused by combined inhibition of p97 and the proteasome. We found that p97 inhibition elicits cellular responses that are different from those induced by proteasome inhibition, and that the responses differ considerably between MMC lines. Moreover, we found that dual inhibition of both p97 and the proteasome terminally disrupts ER configuration and intracellular protein metabolism in MMCs. Dual inhibition of p97 and the proteasome induced high levels of apoptosis in all of the MMC lines that we analysed, including bortezomib-adapted AMO-1 cells, and was also effective in killing primary MMCs. Only minor toxicity was observed in untransformed and non-secretory cells. Our observations highlight non-redundant roles of p97 and the proteasome in maintaining secretory homeostasis in MMCs and provide a preclinical conceptual framework for dual targeting of p97 and the proteasome as a potential new therapeutic strategy in multiple myeloma.

UR - http://www.scopus.com/inward/record.url?scp=84884268185&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84884268185&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0074415

DO - 10.1371/journal.pone.0074415

M3 - Article

C2 - 24069311

AN - SCOPUS:84884268185

VL - 8

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 9

M1 - e74415

ER -